BSD-2000 Clinical Studies

Authors: Fotopoulou C, Cho CH, Kraetschell R, Gellermann J, Wust P, Lichtenegger W, Sehouli J.
Publication: Int J Hyperthermia. 2010;26(2):118-26. doi: 10.3109/02656730903369200.

PURPOSE:
Due to the poor prognosis of patients with ovarian cancer relapse (OCR), newer strategies are warranted to improve the therapeutic index. We performed a prospective phase I/II-study of regional abdominal hyperthermia (RHT) combined with systemic chemotherapy in OCR patients in order to evaluate outcome, efficacy and tolerance.

Authors: Schlemmer M, Wendtner CM, Lindner L, Abdel-Rahman S, Hiddemann W, Issels RD.
Publication: Int J Hyperthermia. 2010;26(2):127-35. doi: 10.3109/02656730903335995.

PURPOSE:

We report data from phase II trials examining the efficacy of multimodality treatment with neoadjuvant chemotherapy, hyperthermia, surgery, radiation and postoperative thermochemotherapy in adult patients with high-risk sarcomas of the extremities.

Authors: Wittlinger M, Rödel CM, Weiss C, Krause SF, Kühn R, Fietkau R, Sauer R, Ott OJ.
Publication: Radiother Oncol. 2009 Nov;93(2):358-63. doi: 10.1016/j.radonc.2009.09.018.

PURPOSE:
To assess the safety and effectiveness of treating high-risk T1 and T2 bladder cancer with transurethral resection (TUR-BT) followed by radiochemotherapy (RCT) combined with regional deep hyperthermia (RHT).

Authors: Scully SP, Oleson JR, Leopold KA, Samulski TV, Dodge R, Harrelson JM.
Publication: J Surg Oncol. 1994 Nov;57(3):143-51.

PURPOSE:
In the treatment of soft tissue sarcomas, hyperthermia has been demonstrated to enhance tumor necrosis from radiation therapy. The current study reports the clinical course of patients treated with this neoadjuvant therapy regimen.

Authors: Kaplan I, Kapp DS, Bagshaw MA.
Publication: Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):551-4.

ABSTRACT:
At Stanford, six patients underwent a course of external radiotherapy after local recurrence following 125-iodine implantation.

Authors: Myerson RJ, Leybovich L, Emami B, Grigsby PW, Straube W, Von Gerichten D.
Publication: Int J Hyperthermia. 1991 Nov-Dec;7(6):937-51.

PURPOSE:
The BSD 2000 system is an array of microwave antennas operating in the 60-120 MHz range. It is a four-quadrant regional hyperthermia device with phase control permitting the operator to choose the point of constructive interference. A computer preplanning system is provided.

Authors: Wessalowski R, Schneider DT, Mils O, Hannen M, Calaminus G, Engelbrecht V, Pape H, Willers R, Engert J, Harms D, Göbel U.
Publication: Klin Padiatr. 2003 Nov-Dec;215(6):303-9.

BACKGROUND:
Elevated temperatures of 40 - 44 degrees C increase the actions of various anticancer drugs including N-lost derivatives, cytotoxic antibiotics and platinum analoga. In clinical usage thermochemotherapy (TCH) should facilitate surgical resection and ameliorate local tumor control.

Table Article Count: 12

Page 4 of 9

BSD-2000 Published Clinical Studies

Phase I, II & III Clinical Studies that used the BSD-2000

Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study

Thermochemotherapy in patients with extremity high-risk soft tissue sarcomas (HR-STS)

Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia

Clinical outcome after neoadjuvant thermoradiotherapy in high grade soft tissue sarcomas

Secondary external-beam radiotherapy and hyperthermia for local recurrence after 125-iodine implantation in adenocarcinoma of the prostate

Phantom studies and preliminary clinical experience with the BSD 2000

An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors

Table Article Count: 12